Physician profile
Ashith Mally
NPI 1609849157
$5,309.20
in general payments reported to CMS, 2019-2025
47 companies · $909 in 2025
The $909 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $318 · 2021: $497 · 2022: $523 · 2023: $694 · 2024: $800 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,403.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.79 | 2019-2025 | |
| Lilly USA, LLC | $650.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $479.91 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $475.71 | 2019-2025 | |
| Novo Nordisk INC | $371.83 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $232.80 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.79 | 2019-2025 | Jardiance |
| Amgen INC. | $176.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $145.22 | 2019-2022 | |
| Amarin Pharma, INC. | $120.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $78.21 | 2019-2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Daiichi Sankyo INC. | $71.22 | 2019-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $64.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $62.04 | 2019-2020 | |
| Vivus LLC | $45.98 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashith Mally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.